Change search
ReferencesLink to record
Permanent link

Direct link
Serum metabolite profile associates with the development of metabolic co-morbidities in first-episode psychosis
Steno Diabetes Center, Gentofte, Denmark.
Mental Health Unit, National Institute for Health and Welfare, Helsinki, Finland; Department of Psychiatry, McGill University, Montréal, QC, Canada; Bipolar Disorders Clinic, Douglas Mental Health University Institute, Montréal, QC, Canada.
Mental Health Unit, National Institute for Health and Welfare, Helsinki, Finland; Department of Psychiatry, Helsinki University and Helsinki University Hospital, Helsinki, Finland.
Steno Diabetes Center, Gentofte, Denmark.
Show others and affiliations
2016 (English)In: Translational Psychiatry, ISSN 2158-3188, E-ISSN 2158-3188, Vol. 6, no 11, e951Article in journal (Refereed) Published
Abstract [en]

Psychotic patients are at high risk for developing obesity, metabolic syndrome and type 2 diabetes. These metabolic co-morbidities are hypothesized to be related to both treatment side effects as well as to metabolic changes occurring during the psychosis. Earlier metabolomics studies have shown that blood metabolite levels are predictive of insulin resistance and type 2 diabetes in the general population as well as sensitive to the effects of antipsychotics. In this study, we aimed to identify the metabolite profiles predicting future weight gain and other metabolic abnormalities in psychotic patients. We applied comprehensive metabolomics to investigate serum metabolite profiles in a prospective study setting in 36 first-episode psychosis patients during the first year of the antipsychotic treatment and 19 controls. While corroborating several earlier findings when comparing cases and controls and the effects of the antipsychotic medication, we also found that prospective weight gain in psychotic patients was associated with increased levels of triacylglycerols with low carbon number and double-bond count at baseline, that is, lipids known to be associated with increased liver fat. Our study suggests that metabolite profiles may be used to identify the psychotic patients most vulnerable to develop metabolic co-morbidities, and may point to a pharmacological approach to counteract the antipsychotic-induced weight gain.

Place, publisher, year, edition, pages
London. United Kingdom: Nature Publishing Group, 2016. Vol. 6, no 11, e951
National Category
URN: urn:nbn:se:oru:diva-53599DOI: 10.1038/tp.2016.222PubMedID: 27845774OAI: oai:DiVA.org:oru-53599DiVA: diva2:1048638
Available from: 2016-11-21 Created: 2016-11-21 Last updated: 2016-11-21Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Hyötyläinen, Tuulia
By organisation
School of Science and Technology, Örebro University, Sweden
In the same journal
Translational Psychiatry

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 32 hits
ReferencesLink to record
Permanent link

Direct link